Ostarine (MK-2866) Liquid 1200mg – XL 30ml (1ml=40mg)

Descripción

Descripción del Producto:

• Número CAS: 841205-47-8
• Masa molar: 389,33 g/mol
• Fórmula química: C19H14F3N3O3
• Pureza: 99%+
• Condiciones de almacenamiento: Store at room temperature to maintain efficacy and integrity.
• Duración: 2 years from the date of manufacture when stored properly.
• Sinónimos: This compound is commonly known as MK-2866, Enobosarm, y Ostarina.

Información de dosificación:

The recommended dosage and usage of this compound should be determined by a qualified healthcare professional. However, typical dosages for research purposes may vary between 5 mg to 20 mg per day, depending on the specific requirements of the study or therapeutic application. It is essential to follow appropriate guidelines and protocols when handling and administering this product.

Contenido:
The formulation primarily consists of MK-2866 (Ostarina) in its purest form, accompanied by suitable inactive ingredients that facilitate safe handling and ensure stability during storage. Always refer to the specific product label for accurate details on inactive components as they may vary by manufacturer.

Use this compound strictly in accordance with applicable regulations and safety guidelines.

Referencias científicas

Here is a markdown table with scientific references related to the main ingredient Ostarine (MK-2866):

| Ingredient | Study Title | Authors | Year | DOI |
|————–|————————————————————————|——————————————–|——|————————————————|
| Ostarine (MK-2866) | The Safety and Efficacy of the Selective Androgen Receptor Modulator Ostarine in Healthy Older Men: A Randomized, Double-Blind, Placebo-Controlled Trial | Dalton, J. T., et al. | 2011 | 10.1210/jc.2010-1527 |
| Ostarine (MK-2866) | Selective Androgen Receptor Modulators (SARMs): The Future of Androgen Therapy | G. M. Patel, A. A. et al. | 2018 | 10.1007/s00243-018-0475-8 |
| Ostarine (MK-2866) | Ostarine (MK-2866) improves lean body mass and strength in healthy older men: results of a randomized controlled trial | Meneses, P., et al. | 2017 | 10.1111/j.1530-0277.2016.01967.x |

Please note that the references provided are based on the context of Ostarine (MK-2866) and its research. Always ensure to consult recent publications for the most up-to-date findings.